We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ZTS Q2 EPS beat estimates. Revenues were flat year over year and slightly missed expectations.
ZTS now expects 2026 revenues of $9.12B-$9.32B and adjusted EPS of $6.15-$6.25, both down from prior outlook.
Zoetis faced weaker U.S. companion animal sales, while international and U.S. livestock sales grew.
Zoetis, Inc. (ZTS - Free Report) delivered second-quarter 2026 adjusted earnings (excluding one-time items) of $1.87 per share, which beat the Zacks Consensus Estimate of $1.84. In the year-ago quarter, the company had delivered adjusted earnings of $1.76 per share.
Total revenues were flat year over year at $2.47 billion in the second quarter and marginally missed the Zacks Consensus Estimate of $2.49 billion.
Year to date, shares of Zoetis have plunged 40% compared with the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
ZTS’ Q2 Results in Detail
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Revenues from the U.S. segment decreased 7% year over year to $1.30 billion in the reported quarter, missing the Zacks Consensus Estimate of $1.33 billion.
Sales of companion animal products in the U.S. region declined 11% year over year to $1.04 billion, owing to softer end-market demand and an increasingly competitive landscape. Zoetis’ key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity. Also, generic competition for the Convenia and Cerenia brands, as well as lower sales of ZTS’ monoclonal antibody product for osteoarthritis (OA) pain, Librela, for dogs, resulted in the decline.
Sales of livestock products in the United States increased 23% in the quarter to $222 million. The increase was mainly due to broad-based strength across cattle and poultry products.
Revenues in the International segment increased 8% year over year on a reported basis and 6% on an operational basis to $1.17 billion, beating the Zacks Consensus Estimate of $1.14 billion.
Ex-U.S. sales of companion animal products rose 8% on a reported basis and 5% operationally to $664 million, driven by growth in the parasiticides portfolio, including Simparica Trio, along with contributions from Revolution and Stronghold. Growth was also supported by companion animal diagnostics and the OA pain portfolio, following the launches of Lenivia and Portela.
Livestock product sales increased 8% year over year on a reported basis and 6% operationally to $509 million, driven by growth in cattle and poultry.
ZTS’ 2026 Guidance
Zoetis lowered its revenue and earnings outlook for 2026.
The company now expects revenues to be in the range of $9.12 billion and $9.32 billion, reflecting an expected operational growth of negative 1-3%.
Previously, the company projected revenues between $9.68 billion and $9.96 billion, representing an expected operational growth of 2-5%.
Adjusted earnings are now expected in the range of $6.15-$6.25 per share in 2026, compared with the previous expectation of $6.85-$7.00 per share.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.4% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Shutterstock
Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
Key Takeaways
Zoetis, Inc. (ZTS - Free Report) delivered second-quarter 2026 adjusted earnings (excluding one-time items) of $1.87 per share, which beat the Zacks Consensus Estimate of $1.84. In the year-ago quarter, the company had delivered adjusted earnings of $1.76 per share.
Total revenues were flat year over year at $2.47 billion in the second quarter and marginally missed the Zacks Consensus Estimate of $2.49 billion.
Year to date, shares of Zoetis have plunged 40% compared with the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
ZTS’ Q2 Results in Detail
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Revenues from the U.S. segment decreased 7% year over year to $1.30 billion in the reported quarter, missing the Zacks Consensus Estimate of $1.33 billion.
Sales of companion animal products in the U.S. region declined 11% year over year to $1.04 billion, owing to softer end-market demand and an increasingly competitive landscape. Zoetis’ key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity. Also, generic competition for the Convenia and Cerenia brands, as well as lower sales of ZTS’ monoclonal antibody product for osteoarthritis (OA) pain, Librela, for dogs, resulted in the decline.
Sales of livestock products in the United States increased 23% in the quarter to $222 million. The increase was mainly due to broad-based strength across cattle and poultry products.
Revenues in the International segment increased 8% year over year on a reported basis and 6% on an operational basis to $1.17 billion, beating the Zacks Consensus Estimate of $1.14 billion.
Ex-U.S. sales of companion animal products rose 8% on a reported basis and 5% operationally to $664 million, driven by growth in the parasiticides portfolio, including Simparica Trio, along with contributions from Revolution and Stronghold. Growth was also supported by companion animal diagnostics and the OA pain portfolio, following the launches of Lenivia and Portela.
Livestock product sales increased 8% year over year on a reported basis and 6% operationally to $509 million, driven by growth in cattle and poultry.
ZTS’ 2026 Guidance
Zoetis lowered its revenue and earnings outlook for 2026.
The company now expects revenues to be in the range of $9.12 billion and $9.32 billion, reflecting an expected operational growth of negative 1-3%.
Previously, the company projected revenues between $9.68 billion and $9.96 billion, representing an expected operational growth of 2-5%.
Adjusted earnings are now expected in the range of $6.15-$6.25 per share in 2026, compared with the previous expectation of $6.85-$7.00 per share.
Zoetis Inc. Price, Consensus and EPS Surprise
Zoetis Inc. price-consensus-eps-surprise-chart | Zoetis Inc. Quote
ZTS’ Zacks Rank and Stocks to Consider
Zoetis currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.4% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.